Literature DB >> 11249694

VP-14637 ViroPharma.

J McKimm-Breschkin1.   

Abstract

VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11249694

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  12 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Blocking Respiratory Syncytial Virus Entry: A Story with Twists.

Authors:  Marco Weisshaar; Robert Cox; Richard K Plemper
Journal:  DNA Cell Biol       Date:  2015-05-11       Impact factor: 3.311

Review 3.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

4.  Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Xiaowu Chen; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 5.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.

Authors:  Dharmaraj Samuel; Weimei Xing; Anita Niedziela-Majka; Jinny S Wong; Magdeleine Hung; Katherine M Brendza; Michel Perron; Robert Jordan; David Sperandio; Xiaohong Liu; Richard Mackman; Roman Sakowicz
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

7.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.

Authors:  Christopher Cianci; Eugene V Genovesi; Lucinda Lamb; Ivette Medina; Zheng Yang; Lisa Zadjura; Hyekyung Yang; Celia D'Arienzo; Ny Sin; Kuo-Long Yu; Keith Combrink; Zhufang Li; Richard Colonno; Nicholas Meanwell; Junius Clark; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 9.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 10.  Respiratory syncytial virus entry inhibitors targeting the F protein.

Authors:  Zhiwu Sun; Yanbin Pan; Shibo Jiang; Lu Lu
Journal:  Viruses       Date:  2013-01-16       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.